December 10, 2025
Our lab is excited to announce a new collaboration with Tezcat Biosciences, supported by a Phase II SBIR award from the National Cancer Institute. Together, we will conduct advanced preclinical testing of TZT-102 in KRAS-mutant pancreatic cancer, leveraging patient-derived xenograft (PDX) models to explore new therapeutic opportunities. This partnership bridges biotech innovation with academic translational research, with the shared goal of improving outcomes for patients with one of the most challenging cancers. Learn more about Tezcat Biosciences.